3 8 4 8 0

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊










更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

视频

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD

 

Authors Calverley PMA, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA

Received 10 October 2017

Accepted for publication 19 February 2018

Published 23 April 2018 Volume 2018:13 Pages 1297—1308

DOI https://doi.org/10.2147/COPD.S153631

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Rationale: Exacerbations of COPD are managed differently, but whether treatment of one exacerbation predicts the likelihood of subsequent events is unknown.
Objective: We examined whether the treatment given for exacerbations predicted subsequent outcomes.
Methods: This was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety and Performance In Respimat
® (TIOSPIR®). Patients treated with tiotropium with one or more moderate to severe exacerbations on study were analyzed using descriptive statistics, logistic and Cox regression analysis, and Kaplan–Meier plots.
Results: Of 8,061 patients with moderate to severe exacerbation(s), demographics were similar across patients with exacerbations treated with antibiotics and/or steroids or hospitalization. Exacerbations treated with systemic corticosteroids alone or in combination with antibiotics had the highest risk of subsequent exacerbation (HR: 1.21, =0.0004 and HR: 1.33, <0.0001, respectively), and a greater risk of having a hospitalized (severe) exacerbation (HR: 1.59 and 1.63, <0.0001, respectively) or death (HR: 1.50, =0.0059 and HR: 1.47, =0.0002, respectively) compared with exacerbations treated with antibiotics alone. Initial hospitalization led to the highest risk of subsequent hospitalization (all-cause or COPD related [severe exacerbation], HR: 3.35 and 4.31, <0.0001, respectively) or death (all-cause or COPD related, HR: 3.53 and 5.54, <0.0001, respectively) versus antibiotics alone.
Conclusion: These data indicate that the way exacerbations are treated initially is a useful guide to the patient’s subsequent clinical course. Factors that clinicians consider when making treatment choices require further clarification.
Keywords: tiotropium, TIOSPIR
®, severity, exacerbations of COPD, hospitalization


 

摘要视频链接TIOSPIR®: outcomes by index exacerbation severity